Maybe, just maybe, one or more COVID-19 vaccines could be on the way. Five novel coronavirus vaccines are currently in late-stage testing. If all goes well, Americans could possibly have access to a COVID-19 vaccine that's safe and effective in the first half of next year.
As you might expect, it costs a lot of money to develop vaccines. Should you brace for a steep price tag for a COVID-19 vaccine? Actually, no. You might be surprised by how much you'll have to pay for a coronavirus vaccine.
A good kind of sticker shock
Flu vaccines typically cost in the ballpark of $40. A new shingles vaccine can cost nearly $300 for two shots. Will a COVID-19 vaccine's cost be somewhere in the middle? Nope. Guess lower. Much lower.
The U.S. Department of Health and Human Services (HHS) intends to make COVID-19 vaccines available to Americans at no cost. That's right, the price tag for you will be $0.
We're not talking about only Medicare members. The no-cost offer isn't just for individuals with low incomes. HHS publicly stated that an approved COVID-19 vaccine will be free "to the American people." That includes everyone, regardless of age, income, or the type of health plan you have.
Granted, there could be some money changing hands. Your healthcare provider will be allowed to charge insurers for the cost of administering the COVID-19 vaccine. That's normal with vaccines purchased by the government, though. And it will be the insurance company forking over cash instead of you.
The price you won't see but will still pay
You've probably heard the expression that there's no such thing as a free lunch. Well, there's also no such thing as a free vaccine. There's a price tag for COVID-19 vaccines that you won't see but will still probably pay.
It's sometimes easy to forget that when the U.S. government buys something, taxpayers are the ones ultimately footing the bill. If you pay federal taxes, you will indirectly pay for COVID-19 vaccines.
The U.S. government plans to buy 100 million doses of the COVID-19 vaccine developed by Pfizer (NYSE: PFE) and BioNTech, assuming the two drugmakers' lead candidate wins FDA approval or Emergency Use Authorization. It's paying $1.95 billion, which amounts to a price of $19.50 per dose.
Spreading that $1.95 billion cost across roughly 119.5 million taxpayers comes to a little over $16 per taxpayer. However, you're really paying more than that.
In March, HHS announced that it would provide $456 million in funding for Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine candidate. The department committed up to $483 million in April for Moderna's (NASDAQ: MRNA) experimental coronavirus vaccine.
In May, HHS agreed to pay up to $1.2 billion to AstraZeneca (NYSE: AZN) to support the development and manufacturing of its COVID-19 vaccine candidate AZD1222. And in July, the U.S. government signed a deal with Novavax to get 100 million doses of its COVID-19 vaccine candidate in exchange for funding of $1.6 billion.
Just last week, Sanofi and GlaxoSmithKline won a deal with the U.S. government to supply 100 million doses of their vaccine candidate that's currently in preclinical testing. The price tag of this agreement totaled up to $2.1 billion, including funding for the clinical development process.
In addition to these agreements, HHS is paying Emergent BioSolutions $628 million under an existing contract with the Biomedical Advanced Research and Development Authority (BARDA). Some of this amount targets manufacturing a COVID-19 vaccine, but some also will go toward Emergent BioSolutions helping make therapeutics for the novel coronavirus disease.
Even if we exclude the HHS deal with Emergent, the U.S. government is paying more than $6.1 billion in total for COVID-19 vaccines. That means each American taxpayer's portion of the bill comes to over $51. Clearly, the "no-cost" coronavirus vaccine that hopefully is on the way won't really be free.
The price tag for COVID-19 vaccines is also likely to increase. For example, both AstraZeneca and J&J have said they won't try to make a profit from their vaccines during the pandemic. But there could still be high demand for COVID-19 vaccines even after the pandemic officially ends. That could set the stage for the big pharma companies to raise their prices.
There will also almost certainly be a limit on how many vaccine doses the U.S. government will purchase and make available at no cost. Once the current healthcare crisis is over, you might have to pay some amount out of pocket for a COVID-19 vaccine.
How much could that amount be? Moderna could provide a hint. The biotech is reportedly considering pricing its COVID-19 vaccine at between $50 and $60 per dose in the U.S. Other drugmakers could eventually set their prices in this general ballpark, too.
Rising prices in the future in the world of healthcare? That's no surprise at all.
10 stocks we like better than Pfizer
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Pfizer wasn't one of them! That's right -- they think these 10 stocks are even better buys.
*Stock Advisor returns as of June 2, 2020
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.